Salt-inducible kinase inhibitor compound and pharmaceutical composition including the same

A compound represented by formula (I) below or a pharmacologically acceptable salt thereof:

• wherein
• R1 is a cyano group, a C1-4 alkyl group optionally substituted with one to three halogen atoms, or a C1-4 alkoxy group optionally substituted with one to three substituents independently selected from R1a,
• wherein R1a is a halogen atom;
• a 5- or 6-membered monocyclic aromatic heterocyclic group optionally substituted with one to three substituents independently selected from the group consisting of cyano groups, halogen atoms, and C1-4 alkyl groups;
• a 4-membered monocyclic aliphatic heterocyclic group;
• a hydroxyl group;
• a C3-4 cycloalkyl group;
• and a phenyl group,
• L is a single bond, a C1-4 alkylene group, or a C2-4 alkenylene group,
• R2 is a 5-membered monocyclic aromatic heterocyclic group optionally substituted with R2a,
• wherein R2a is a C1-5 alkyl group optionally substituted with one to four substituents independently selected from R2b, or a 5-membered monocyclic aliphatic heterocyclic group,
• wherein R2b is a hydroxyl group;
• a C3-4 cycloalkyl group optionally substituted with a hydroxyl group;
• a halogen atom;
• a C1-4 alkoxy group;
• a 4- to 6-membered monocyclic aliphatic heterocyclic group optionally substituted with one to three substituents independently selected from the group consisting of halogen atoms and oxo groups;
• an oxo group;
• an amino group optionally substituted with one or two C1-4 alkyl groups;
• a phenyl group;
• a 5-membered monocyclic aromatic heterocyclic group;
• and a C1-4 alkylsulfonyl group,
• R3 is a hydrogen atom or a C1-4 alkoxy group optionally substituted with one to three halogen atoms,
• R4 is a C1-4 alkoxy group optionally substituted with one to three halogen atoms,
• R5 is a hydrogen atom,
• R6 is a hydrogen atom;
• a C1-4 alkyl group substituted with a halocyclopropyl group;
• or a cyclopropyl group substituted with one or two halogen atoms, or
• R5 and R6, taken together with the nitrogen atom to which they are bonded, form an azetidine ring wherein the azetidine ring is substituted with one or two substituents independently selected from the group consisting of C1-4 alkyl groups optionally substituted with one to three halogen atoms;
• hydroxyl groups;
• C1-4 alkoxy groups optionally substituted with one or two halogen atoms;
• cyano groups;
• and amino groups, or
• R4 and R6, taken together with the benzene ring to which R4 is bonded, form a tetrahydroisoquinolin-1-one ring wherein the ring is substituted with one or two C1-4 alkyl groups.